MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
DENTSPLY SIRONA Interest Expense 2011-2026 | XRAY
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense DENTSPLY SIRONA
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 M | 12 M | -9 M | -53 M | 61 M | -1 M | 12 M | 37.3 M | 38.3 M | 35.9 M | 55.9 M | 46.9 M | 49.6 M | 56.9 M | 43.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 61 M | -53 M | 27.4 M |
Quarterly Interest Expense DENTSPLY SIRONA
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 M | - | 11 M | -1 M | - | - | 2 M | 1 M | 7 M | - | 5 M | -12 M | 20 M | - | 14 M | 15 M | 12 M | - | 14 M | 15 M | 14 M | - | 14 M | 11 M | 7 M | - | 6.6 M | 8 M | 8.4 M | - | 9.7 M | 9.6 M | 8.6 M | - | 9.8 M | 9.6 M | 9.3 M | - | 8.4 M | 9.3 M | 9.2 M | - | 9.6 M | 9.8 M | 10.7 M | - | 12.7 M | 11.8 M | 11 M | - | 11.4 M | 11.5 M | 15.2 M | - | 13.9 M | 14.3 M | 15.8 M | - | 16.1 M | 5.57 M | 6.34 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20 M | -12 M | 9.96 M |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
-16.4 M | $ 60.38 | - | $ 12 B |  USA |
 |
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | USA |
 |
Repro Med Systems
KRMD
|
9.91 K | $ 3.98 | - | $ 184 M | USA |
 |
ICU Medical
ICUI
|
93.3 M | $ 122.99 | 0.78 % | $ 3.03 B | USA |
 |
iRhythm Technologies
IRTC
|
5.44 M | $ 114.16 | - | $ 3.65 B | USA |
 |
Alcon
ALC
|
204 M | $ 64.0 | -0.03 % | $ 40.4 B |  Schweiz |
 |
LeMaitre Vascular
LMAT
|
5.18 M | $ 99.5 | - | $ 2.25 B | USA |
 |
Masimo Corporation
MASI
|
300 K | $ 178.35 | - | $ 9.51 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-26 K | - | - | $ 28.6 M | USA |
 |
Envista Holdings Corporation
NVST
|
-2.3 M | $ 23.86 | - | $ 4.01 B | USA |
 |
electroCore
ECOR
|
14.9 K | $ 6.43 | - | $ 54.5 K | USA |
 |
Haemonetics Corporation
HAE
|
-9.75 M | $ 57.12 | - | $ 2.87 B | USA |
 |
Isoray
ISR
|
84 K | - | 0.03 % | $ 108 M | USA |
 |
STAAR Surgical Company
STAA
|
2.25 M | $ 32.01 | - | $ 1.59 B | USA |
 |
Glaukos Corporation
GKOS
|
13.6 M | $ 142.15 | - | $ 6.88 B | USA |
 |
STERIS plc
STE
|
8.4 M | $ 215.98 | - | $ 21.3 B | USA |
 |
Teleflex Incorporated
TFX
|
85.1 M | $ 130.28 | - | $ 5.81 B | USA |
 |
InfuSystem Holdings
INFU
|
2 K | $ 8.61 | - | $ 178 M | USA |
 |
Microbot Medical
MBOT
|
-5 K | $ 1.85 | - | $ 84.7 M |  Israel |
 |
Milestone Scientific
MLSS
|
60.3 K | $ 0.34 | -0.87 % | $ 27.9 M | USA |
 |
Merit Medical Systems
MMSI
|
-2.39 M | $ 62.56 | - | $ 3.7 B | USA |
 |
Utah Medical Products
UTMD
|
-120 K | $ 63.7 | - | $ 206 M | USA |
 |
West Pharmaceutical Services
WST
|
-1 M | $ 300.19 | - | $ 21.7 B | USA |
 |
Pulse Biosciences
PLSE
|
-52 K | $ 27.1 | - | $ 1.83 B | USA |
 |
Retractable Technologies
RVP
|
227 K | $ 0.69 | 0.01 % | $ 20.7 M | USA |
 |
Pro-Dex
PDEX
|
533 K | $ 58.65 | - | $ 193 M | USA |
 |
Predictive Oncology
POAI
|
3 | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
1.82 M | $ 21.06 | - | $ 1.01 B | USA |
 |
Stereotaxis
STXS
|
2 K | $ 1.94 | - | $ 176 M | USA |
 |
Baxter International
BAX
|
290 M | $ 17.78 | - | $ 9.12 B | USA |
 |
ResMed
RMD
|
3.2 M | $ 202.46 | - | $ 29.6 B | USA |
 |
AtriCure
ATRC
|
683 K | $ 28.15 | - | $ 1.34 B | USA |
 |
Harvard Bioscience
HBIO
|
-2.66 M | $ 5.52 | - | $ 245 M | USA |
 |
AngioDynamics
ANGO
|
4.94 M | $ 11.03 | - | $ 451 M | USA |
 |
Becton, Dickinson and Company
BDX
|
613 M | $ 144.47 | - | $ 41.6 B | USA |
 |
Nephros
NEPH
|
-78 K | $ 3.34 | - | $ 35.4 M | USA |
 |
OraSure Technologies
OSUR
|
229 K | $ 2.95 | - | $ 217 M | USA |
 |
Repligen Corporation
RGEN
|
2.82 M | $ 103.38 | - | $ 5.81 M | USA |